Recreational Marijuana Use, Adolescent Cognitive Development, and Schizophrenia Susceptibility.
Brain maturation
Cannabis
Genetic susceptibility
Longitudinal study
Schizophrenia
Journal
Biological psychiatry global open science
ISSN: 2667-1743
Titre abrégé: Biol Psychiatry Glob Open Sci
Pays: United States
ID NLM: 9918227369306676
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
22
10
2021
revised:
26
01
2022
accepted:
28
01
2022
medline:
8
2
2022
pubmed:
8
2
2022
entrez:
1
5
2023
Statut:
epublish
Résumé
We investigated how low marijuana (MJ) use levels, the typical use pattern in most adolescent users, affect cognitive maturation and schizophrenia risk. In two complementary adolescent samples where the majority reported minimal MJ use, we compared cognitive performances before and after MJ use initiation. The Iowa sample (40 first-degree relatives and 54 second-degree relatives of patients with schizophrenia and 117 control subjects with no schizophrenia family history) underwent a battery of standardized neuropsychological tests at 0, 18, and 36 months. Based on self-administered Timeline Followback interviews, 26.5% of adolescents had emergent MJ use (eMJ) during follow-up. The second sample ( In the Iowa sample, longitudinal changes in 5 of 8 cognitive domains were significantly associated with eMJ. On sustained attention, visuospatial working memory, and executive sequencing, adolescents with eMJ showed less age-expected improved performance. In addition, first-degree relatives with eMJ were less improved on processing speed and executive reasoning than first-degree relatives without eMJ. In the birth cohort, greater intraindividual variability in reaction times (indicative of poorer sustained attention) was significantly associated with more frequent MJ use and with recreational use levels. Nonheavy MJ use disrupts normal adolescent maturation and compounds aberrant adolescent maturation associated with familial schizophrenia risk. These findings underscore the importance of reducing adolescent MJ access in the context of increased availability to high-potency MJ.
Sections du résumé
Background
UNASSIGNED
We investigated how low marijuana (MJ) use levels, the typical use pattern in most adolescent users, affect cognitive maturation and schizophrenia risk.
Methods
UNASSIGNED
In two complementary adolescent samples where the majority reported minimal MJ use, we compared cognitive performances before and after MJ use initiation. The Iowa sample (40 first-degree relatives and 54 second-degree relatives of patients with schizophrenia and 117 control subjects with no schizophrenia family history) underwent a battery of standardized neuropsychological tests at 0, 18, and 36 months. Based on self-administered Timeline Followback interviews, 26.5% of adolescents had emergent MJ use (eMJ) during follow-up. The second sample (
Results
UNASSIGNED
In the Iowa sample, longitudinal changes in 5 of 8 cognitive domains were significantly associated with eMJ. On sustained attention, visuospatial working memory, and executive sequencing, adolescents with eMJ showed less age-expected improved performance. In addition, first-degree relatives with eMJ were less improved on processing speed and executive reasoning than first-degree relatives without eMJ. In the birth cohort, greater intraindividual variability in reaction times (indicative of poorer sustained attention) was significantly associated with more frequent MJ use and with recreational use levels.
Conclusions
UNASSIGNED
Nonheavy MJ use disrupts normal adolescent maturation and compounds aberrant adolescent maturation associated with familial schizophrenia risk. These findings underscore the importance of reducing adolescent MJ access in the context of increased availability to high-potency MJ.
Identifiants
pubmed: 37124347
doi: 10.1016/j.bpsgos.2022.01.008
pii: S2667-1743(22)00013-1
pmc: PMC10140454
doi:
Types de publication
Journal Article
Langues
eng
Pagination
222-232Subventions
Organisme : Medical Research Council
ID : G9815508
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Informations de copyright
© 2022 The Authors.
Références
Q J Exp Psychol (Hove). 2017 Aug;70(8):1722-1731
pubmed: 27328052
Biol Psychiatry. 2016 Apr 1;79(7):613-9
pubmed: 26903403
Stat Methods Med Res. 2018 Jul;27(7):2015-2023
pubmed: 29846144
Psychiatry Res. 2015 Dec 30;230(3):826-34
pubmed: 26586142
Addict Behav. 2007 Sep;32(9):1787-97
pubmed: 17261356
Biol Psychiatry. 2017 Nov 1;82(9):660-668
pubmed: 28237458
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Dev Cogn Neurosci. 2018 Aug;32:67-79
pubmed: 29525452
Annu Rev Psychol. 1992;43:303-36
pubmed: 1539945
Neurotoxicol Teratol. 2005 Mar-Apr;27(2):231-9
pubmed: 15734274
Biol Psychiatry. 2016 Apr 1;79(7):557-67
pubmed: 26858214
Schizophr Bull. 2005 Jul;31(3):608-12
pubmed: 15976013
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E500-8
pubmed: 26787878
J Drug Issues. 2005;35(2):255-279
pubmed: 16534532
Neuropsychologia. 2004;42(14):1910-6
pubmed: 15381021
BMJ. 2002 Nov 23;325(7374):1212-3
pubmed: 12446537
Int J Methods Psychiatr Res. 2013 Mar;22(1):16-26
pubmed: 23519957
Brain Cogn. 2004 Dec;56(3):320-7
pubmed: 15522770
Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):5-15
pubmed: 30671616
Nature. 2015 Nov 19;527(7578):305
pubmed: 26581281
Pediatrics. 2017 Mar;139(3):
pubmed: 28242859
Am J Psychiatry. 2014 Apr;171(4):416-25
pubmed: 24577206
Brain Res. 2009 Feb 9;1253:81-91
pubmed: 19094973
Neuropharmacology. 2009;56 Suppl 1:244-53
pubmed: 18722389
Brain. 2003 Nov;126(Pt 11):2363-80
pubmed: 12876148
Schizophr Bull. 2021 Apr 29;47(3):594-603
pubmed: 33693921
J Psychopharmacol. 2006 Sep;20(5):611-21
pubmed: 16714325
Trends Neurosci. 2006 Aug;29(8):474-80
pubmed: 16820224
Neurobiol Dis. 2015 Jan;73:60-9
pubmed: 25281318
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Clin Psychol Rev. 2013 Aug;33(6):795-811
pubmed: 23872284
Arch Gen Psychiatry. 1977 Oct;34(10):1229-35
pubmed: 911222
Addiction. 2005 May;100(5):612-8
pubmed: 15847618
Am J Psychiatry. 2008 Feb;165(2):203-13
pubmed: 18172019
Addiction. 2018 Feb;113(2):257-265
pubmed: 28734078
BMJ. 2002 Nov 23;325(7374):1199
pubmed: 12446534
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
J Int Neuropsychol Soc. 2017 Oct;23(9-10):893-902
pubmed: 29198276
Eur Neuropsychopharmacol. 2015 Dec;25(12):2404-15
pubmed: 26499171
Am J Psychiatry. 2016 Aug 1;173(8):781-9
pubmed: 27138587
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64
pubmed: 22927402
World Psychiatry. 2016 Oct;15(3):195-204
pubmed: 27717258
JAMA Psychiatry. 2017 Jun 1;74(6):579-588
pubmed: 28445557
Alcohol Clin Exp Res. 2004 Aug;28(8):1236-41
pubmed: 15318123
Lancet Psychiatry. 2018 Dec;5(12):987-1012
pubmed: 30392731
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Eur Neuropsychopharmacol. 2020 Jul;36:181-190
pubmed: 32139186
Neuropsychopharmacology. 2004 Aug;29(8):1558-72
pubmed: 15173844
Biol Psychiatry. 2004 Sep 1;56(5):301-7
pubmed: 15336511